Levodopa in the early treatment of Parkinson's disease.Parkinsonism Relat Disord. 2009 Jan; 15 Suppl 1:S17-20.PR
Abstract
l-dopa has many advantages as initial therapy for Parkinson's disease (PD). It is safer, more efficacious, associated with fewer adverse effects, few interactions, easier for patients to use and for clinicians to prescribe, and cheaper than dopamine (DA) agonists. Although l-dopa is more likely than DA agonists to introduce motor fluctuations and dyskinesia, l-dopa is also more effective in improving motor function. Furthermore, there is no long-term benefit from delaying l-dopa based on the risk of motor complications or psychiatric symptoms. Many investigations have shown that l-dopa does not accelerate disease progression. Now is the time to re-evaluate l-dopa for initial treatment of PD.
Links
MeSH
Pub Type(s)
Journal Article
Review
Language
eng
PubMed ID
19131036
Citation
Murata, Miho. "Levodopa in the Early Treatment of Parkinson's Disease." Parkinsonism & Related Disorders, vol. 15 Suppl 1, 2009, pp. S17-20.
Murata M. Levodopa in the early treatment of Parkinson's disease. Parkinsonism Relat Disord. 2009;15 Suppl 1:S17-20.
Murata, M. (2009). Levodopa in the early treatment of Parkinson's disease. Parkinsonism & Related Disorders, 15 Suppl 1, S17-20. https://doi.org/10.1016/S1353-8020(09)70006-9
Murata M. Levodopa in the Early Treatment of Parkinson's Disease. Parkinsonism Relat Disord. 2009;15 Suppl 1:S17-20. PubMed PMID: 19131036.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Levodopa in the early treatment of Parkinson's disease.
A1 - Murata,Miho,
PY - 2009/1/10/entrez
PY - 2009/3/14/pubmed
PY - 2009/4/1/medline
SP - S17
EP - 20
JF - Parkinsonism & related disorders
JO - Parkinsonism Relat Disord
VL - 15 Suppl 1
N2 - l-dopa has many advantages as initial therapy for Parkinson's disease (PD). It is safer, more efficacious, associated with fewer adverse effects, few interactions, easier for patients to use and for clinicians to prescribe, and cheaper than dopamine (DA) agonists. Although l-dopa is more likely than DA agonists to introduce motor fluctuations and dyskinesia, l-dopa is also more effective in improving motor function. Furthermore, there is no long-term benefit from delaying l-dopa based on the risk of motor complications or psychiatric symptoms. Many investigations have shown that l-dopa does not accelerate disease progression. Now is the time to re-evaluate l-dopa for initial treatment of PD.
SN - 1353-8020
UR - https://www.unboundmedicine.com/medline/citation/19131036/Levodopa_in_the_early_treatment_of_Parkinson's_disease_
DB - PRIME
DP - Unbound Medicine
ER -